Validation of a combined ELISA to detect IgG, IgA and IgM antibody responses to SARS-CoV-2 in mild or moderate non-hospitalised patients

BACKGROUND: Frequently SARS-CoV-2 results in mild or moderate disease with potentially lower concentrations of antibodies compared to those that are hospitalised. Here, we validated an ELISA using SARS-CoV-2 trimeric spike glycoprotein, with targeted detection of IgG, IgA and IgM (IgGAM) using serum...

Descripción completa

Detalles Bibliográficos
Autores principales: Cook, A.M., Faustini, S.E., Williams, L.J., Cunningham, A.F., Drayson, M.T., Shields, A.M., Kay, D., Taylor, L., Plant, T., Huissoon, A., Wallis, G., Beck, S., Jossi, S.E., Perez-Toledo, M., Newby, M.L., Allen, J.D., Crispin, M., Harding, S., Richter, A.G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997147/
https://www.ncbi.nlm.nih.gov/pubmed/33775672
http://dx.doi.org/10.1016/j.jim.2021.113046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997147/
https://www.ncbi.nlm.nih.gov/pubmed/33775672
http://dx.doi.org/10.1016/j.jim.2021.113046

Ejemplares similares